Sartorius Stedim Shares Owned By Insiders vs. Cash Per Share

56S1 Stock  EUR 169.60  6.15  3.50%   
Taking into consideration Sartorius Stedim's profitability measurements, Sartorius Stedim Biotech may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Sartorius Stedim's ability to earn profits and add value for shareholders.
For Sartorius Stedim profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sartorius Stedim to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sartorius Stedim Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sartorius Stedim's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sartorius Stedim Biotech over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Sartorius Stedim's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sartorius Stedim is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sartorius Stedim's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sartorius Stedim Biotech Cash Per Share vs. Shares Owned By Insiders Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sartorius Stedim's current stock value. Our valuation model uses many indicators to compare Sartorius Stedim value to that of its competitors to determine the firm's financial worth.
Sartorius Stedim Biotech is number one stock in shares owned by insiders category among its peers. It also is number one stock in cash per share category among its peers fabricating about  0.02  of Cash Per Share per Shares Owned By Insiders. The ratio of Shares Owned By Insiders to Cash Per Share for Sartorius Stedim Biotech is roughly  41.47 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sartorius Stedim's earnings, one of the primary drivers of an investment's value.

Sartorius Cash Per Share vs. Shares Owned By Insiders

Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Sartorius Stedim

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
73.81 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Sartorius Stedim

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.78 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Sartorius Cash Per Share Comparison

Sartorius Stedim is currently under evaluation in cash per share category among its peers.

Sartorius Stedim Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sartorius Stedim, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sartorius Stedim will eventually generate negative long term returns. The profitability progress is the general direction of Sartorius Stedim's change in net profit over the period of time. It can combine multiple indicators of Sartorius Stedim, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. SARTOR STED operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8200 people.

Sartorius Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sartorius Stedim. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sartorius Stedim position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sartorius Stedim's important profitability drivers and their relationship over time.

Use Sartorius Stedim in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sartorius Stedim position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sartorius Stedim will appreciate offsetting losses from the drop in the long position's value.

Sartorius Stedim Pair Trading

Sartorius Stedim Biotech Pair Trading Analysis

The ability to find closely correlated positions to Sartorius Stedim could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sartorius Stedim when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sartorius Stedim - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sartorius Stedim Biotech to buy it.
The correlation of Sartorius Stedim is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sartorius Stedim moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sartorius Stedim Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sartorius Stedim can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sartorius Stedim position

In addition to having Sartorius Stedim in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Funds Thematic Idea Now

Money Funds
Money Funds Theme
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Sartorius Stock

To fully project Sartorius Stedim's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sartorius Stedim Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sartorius Stedim's income statement, its balance sheet, and the statement of cash flows.
Potential Sartorius Stedim investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sartorius Stedim investors may work on each financial statement separately, they are all related. The changes in Sartorius Stedim's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sartorius Stedim's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.